In a recent transaction, John David Finley, the CEO, CFO, and Director of Palisade Bio, Inc. (NASDAQ:PALI), a company specializing in biological products, has increased his stake in the company. On May 24, 2024, Finley purchased 1,000 shares of Palisade Bio's common stock, investing a total of $4,810 at a price of $4.81 per share.
This purchase is a direct investment, as indicated in the company's latest filings, and reflects the CEO's growing position in the company's equity. Following this transaction, Finley now owns a total of 8,437 shares of Palisade Bio directly. Additionally, through FCW Investments, LLC, of which he is the managing member, Finley indirectly holds an additional 51 shares, exercising sole investment and voting power over these securities.
The acquisition of shares by a company's CEO is often seen as a sign of confidence in the firm's future prospects. Investors commonly monitor such insider transactions for hints about the company's performance and strategic direction.
Palisade Bio has a history that includes previous identities as Seneca Biopharma, Inc., and Neuralstem, Inc., with a focus on developing biological products. The company is incorporated in Delaware and has its business address in Carlsbad, California.
The details of the transaction were disclosed in accordance with regulatory requirements and provide transparency into the actions of Palisade Bio's top executive. Finley's signature on the document confirms the accuracy of the reported information as of May 28, 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.